References Flashcards

1
Q

Beta arrestins

A

Rajagopal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Biased ligands

A

Dewire

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Any pharmacology

A

Rand and Dale Pharmacology 7th edition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

CV drugs or actions

A

Klabunde CV Pharmacology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Beta 1 Arg389Gly

A

Maqbool

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Arg389 diastolic blood

A

Johnson

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Remodelling Arg form

A

Terra

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

del322-325 and Arg 389 - ten fold increase in developing heart failure

A

Small

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

nAChR structure - M2 helices

A

Miyazawa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Pilocarpine and epilepsy

A

Scorza

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Diseases

A

NHS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Dopamine hypothesis

A

Handbook of behavioural neuroscience

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Negative feedback on mesolimbic by mesocortical

A

Pariyadath

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Schizo and amphetamines

A

Breier

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

MPP+ - damage by mitochondrial release of ROS and cell apoptosis

A

Kalivendi

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Optimisation of L-DOPA

A

Brooks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Serotonin and Noradrenaline

A

Moret

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Any drugs on list

A

Mayo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

GABAa and other ligand gated ion channel structures

A

Miller

20
Q

GABAa

A

Jacob

21
Q

Extrasynaptic GABAa vs synaptic GABAa (tonic vs phasic inhibition)

A

Belelli

22
Q

GABAb

A

Frangag

23
Q

Six hallmarks, emerging hallmarks, enabling characteristics, microenvironment

A

Hannahan and Weinberg

24
Q

Approved RTK drugs

A

Imai

25
Q

Cancer hallmarks actual details

A

Molecular biology of cell

26
Q

Hypoxic cell resistance

A

Rockwell

27
Q

Taxanes and p glycoprotein

A

Hendrikx

28
Q

Phamacogenetics and cancer

A

Patel

29
Q

Trastuzumab

A

Vu

30
Q

CTLA-4

A

Laurent

31
Q

CYP3a4 inactivates Irinotecan

A

Sai

32
Q

Oncolytic viruses

A

Kaufman

33
Q

AML syngeneic vs allogeneic

A

Gale

34
Q

Alkylating agents crosslinking

A

Deans

35
Q

Nitrogen mustards e.g. Clorambucil and Oxazophosphorines e.g. Cylcophosphamide

A

Emadi

36
Q

MGMT/AGT

A

Gerson

37
Q

Platinums

A

Wang

38
Q

Topo 2 Inhibitors

A

Hande

39
Q

PARP inhibitors

A

Sonnenblick

40
Q

PGE2

A

Gheun Ho

41
Q

Angiotensin receptors

A

Fhyrquist

42
Q

MAS receptor

A

Santos

43
Q

RAAS polymorphisms

A

Danser

44
Q

PARADIGM study ARNI superior to just ACEi

A

Mcmurray

45
Q

Calcium channel structure

A

Catterall

46
Q

T type calcium channels

A

Chiang

47
Q

CYP2D6 numbers

A

Bradford